Response to comment on “Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications”

por Krebs, M.G., Bennett, I.
Publicado 2021

Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications

por Krebs, M.G., Blay, J.-Y., Le Tourneau, C., Hong, D., Veronese, L., Antoniou, M., Bennett, I.
Publicado 2021

PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL

por Sharp, A., Williams, A., Blagden, S., Plummer, R., Hochhauser, D., Krebs, M. G., Pacey, S., Evans, J., Whelan, S., Nandakumar, S., Rogers, S., Jameson, K. L., Basile, F. G., de Bono, J., Arkenau, H.-T.
Publicado 2022

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

por Westphalen, C. B., Krebs, M. G., Le Tourneau, C., Sokol, E. S., Maund, S. L., Wilson, T. R., Jin, D. X., Newberg, J. Y., Fabrizio, D., Veronese, L., Thomas, M., de Braud, F.
Publicado 2021

Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

por Westphalen, C. B., Krebs, M. G., Le Tourneau, C., Sokol, E. S., Maund, S. L., Wilson, T. R., Jin, D. X., Newberg, J. Y., Fabrizio, D., Veronese, L., Thomas, M., de Braud, F.
Publicado 2021

EPIC: an evaluation of the psychological impact of early-phase clinical trials in cancer patients

por Jittla, P., Graham, D.M., Zhou, C., Halliwell, J., O’Reilly, S., Aruketty, S., Azizi, A., Germetaki, T., Lowe, J., Little, M., Punnett, G., McMahon, P., Benson, L., Carter, L., Krebs, M.G., Thistlethwaite, F.C., Darlington, E., Yorke, J., Cook, N.
Publicado 2022

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

por Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A., Holovanchuk, D., Pedersen, M., McLeary, R., Lorigan, P., Dhomen, N., Fisher, C., Banerji, U., Dean, E., Krebs, M.G., Gore, M., Larkin, J., Marais, R., Springer, C.
Publicado 2021

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

por Basu, B, Krebs, M G, Sundar, R, Wilson, R H, Spicer, J, Jones, R, Brada, M, Talbot, D C, Steele, N, Ingles Garces, A H, Brugger, W, Harrington, E A, Evans, J, Hall, E, Tovey, H, de Oliveira, F M, Carreira, S, Swales, K, Ruddle, R, Raynaud, F I, Purchase, B, Dawes, J C, Parmar, M, Turner, A J, Tunariu, N, Banerjee, S, de Bono, J S, Banerji, U
Publicado 2018